UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs

UTX介导的增强子和染色质重塑通过对ETS和GATA程序的非催化性逆向调控抑制髓系白血病发生。

阅读:5
作者:Malgorzata Gozdecka ,Eshwar Meduri ,Milena Mazan ,Konstantinos Tzelepis ,Monika Dudek ,Andrew J Knights ,Mercedes Pardo ,Lu Yu ,Jyoti S Choudhary ,Emmanouil Metzakopian ,Vivek Iyer ,Haiyang Yun ,Naomi Park ,Ignacio Varela ,Ruben Bautista ,Grace Collord ,Oliver Dovey ,Dimitrios A Garyfallos ,Etienne De Braekeleer ,Saki Kondo ,Jonathan Cooper ,Berthold Göttgens ,Lars Bullinger ,Paul A Northcott ,David Adams ,George S Vassiliou ,Brian J P Huntly

Abstract

The histone H3 Lys27-specific demethylase UTX (or KDM6A) is targeted by loss-of-function mutations in multiple cancers. Here, we demonstrate that UTX suppresses myeloid leukemogenesis through noncatalytic functions, a property shared with its catalytically inactive Y-chromosome paralog, UTY (or KDM6C). In keeping with this, we demonstrate concomitant loss/mutation of KDM6A (UTX) and UTY in multiple human cancers. Mechanistically, global genomic profiling showed only minor changes in H3K27me3 but significant and bidirectional alterations in H3K27ac and chromatin accessibility; a predominant loss of H3K4me1 modifications; alterations in ETS and GATA-factor binding; and altered gene expression after Utx loss. By integrating proteomic and genomic analyses, we link these changes to UTX regulation of ATP-dependent chromatin remodeling, coordination of the COMPASS complex and enhanced pioneering activity of ETS factors during evolution to AML. Collectively, our findings identify a dual role for UTX in suppressing acute myeloid leukemia via repression of oncogenic ETS and upregulation of tumor-suppressive GATA programs.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。